

TOM DAVIS, VIRGINIA,
CHAIRMAN

CHRISTOPHER SHAYS, CONNECTICUT
DAN BURTON, INDIANA
ILEANA ROS-LEHTINEN, FLORIDA
JOHN M. McHUGH, NEW YORK
JOHN L. MICA, FLORIDA
GIL GUTKNECHT, MINNESOTA
MARK E. SOUDER, INDIANA
STEVEN C. LATOURETTE, OHIO
TODD RUSSELL PLATTS, PENNSYLVANIA
CHRIS CANNON, UTAH
JOHN J. DUNCAN, JR., TENNESSEE
CANDICE MILLER, MICHIGAN
MICHAEL R. TURNER, OHIO
DARRELL ISSA, CALIFORNIA
JON C. PORTER, NEVADA
KENNY MARCHANT, TEXAS
LYNN A. WESTMORELAND, GEORGIA
PATRICK T. McHENRY, NORTH CAROLINA
CHARLES W. DENT, PENNSYLVANIA
VIRGINIA FOXX, NORTH CAROLINA
JEAN SCHMIDT, OHIO
BRIAN P. BILBRAY, CALIFORNIA

ONE HUNDRED NINTH CONGRESS

Congress of the United States

House of Representatives

COMMITTEE ON GOVERNMENT REFORM

2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

MAJORITY (202) 225-5074
FACSIMILE (202) 225-3974
MINORITY (202) 225-5051
TTY (202) 225-6852

<http://reform.house.gov>

HENRY A. WAXMAN, CALIFORNIA,
RANKING MINORITY MEMBER

TOM LANTOS, CALIFORNIA
MAJOR R. OWENS, NEW YORK
EDOLPHUS TOWNS, NEW YORK
PAUL E. KANJORSKI, PENNSYLVANIA
CAROLYN B. MALONEY, NEW YORK
ELIJAH E. CUMMINGS, MARYLAND
DENNIS J. KUCINICH, OHIO
DANNY K. DAVIS, ILLINOIS
WM. LACY CLAY, MISSOURI
DIANE E. WATSON, CALIFORNIA
STEPHEN F. LYNCH, MASSACHUSETTS
CHRIS VAN HOLLEN, MARYLAND
LINDA T. SANCHEZ, CALIFORNIA
C.A. DUTCH RUPPERSBERGER,
MARYLAND
BRIAN HIGGINS, NEW YORK
ELEANOR HOLMES NORTON,
DISTRICT OF COLUMBIA

BERNARD SANDERS, VERMONT,
INDEPENDENT

FOR IMMEDIATE RELEASE
August 23, 2006

FOR MORE INFORMATION, CONTACT:
Karen Lightfoot/Molly Gulland: (202) 225-5051

REP. WAXMAN REQUESTS FDA INVESTIGATION OF EFFECTIVENESS OF PHENYLEPHRINE ORAL NASAL DECONGESTANTS

WASHINGTON, DC — Today Rep. Henry A. Waxman called on the Federal Food and Drug Administration (FDA) to investigate whether the oral nasal decongestant phenylephrine is effective.

“While I applaud the much-needed efforts to combat the methamphetamine epidemic, we cannot let companies market ineffective products as an alternative to drugs that are now behind the counter,” said Rep. Waxman. “FDA needs to ensure consumers that phenylephrine oral nasal decongestants will safely and effectively relieve their symptoms.”

The 2006 reauthorization of the Patriot Act contained anti-methamphetamine legislation that requires all products containing pseudoephedrine — one of the ingredients used to make methamphetamines — to be moved behind the counter by September 30, 2006. In response to this mandate, manufacturers have begun to offer reformulated oral nasal decongestants that eliminate pseudoephedrine and rely instead on phenylephrine, which permits them to be sold over-the-counter without any restrictions.

However, in a peer-reviewed letter to the editor recently published in the Journal of Allergy and Clinical Immunology, two University of Florida researchers concluded that there is virtually no evidence to show that phenylephrine oral nasal decongestants at the FDA-sanctioned dose of 10 mg are effective.

A copy of Rep. Waxman’s letter to FDA is online at www.democrats.reform.house.gov.